Picture of Karuna Therapeutics logo

KRTX Karuna Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Momentum

Relative Strength (%)
1m+1.04%
3m+39.04%
6m+58.68%
1yr+33.33%
Volume Change (%)
10d/3m+6.97%
Price vs... (%)
52w High-0.05%
50d MA+3.92%
200d MA+44.47%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value10.03
Price to Tang. Book10.03
Price to Free Cashflown/a
Price to Sales19,238.9
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-39.02%
Return on Equity-36.44%
Operating Margin-75653.98%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Karuna Therapeutics EPS forecast chart

Profile Summary

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its pipeline built on the therapeutic potential of its lead product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. It is developing KarXT for the treatment of acute psychosis in adults with schizophrenia, and for the treatment of psychosis in Alzheimer's disease. Its pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, and pre-clinical muscarinic, TRPC4/5 and target-agnostic compounds for the treatment of psychiatric and neurological conditions.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
July 24th, 2009
Public Since
June 28th, 2019
No. of Shareholders
4
No. of Employees
339
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
38,199,272

KRTX Share Price Performance

Upcoming Events for KRTX

Q1 2024 Karuna Therapeutics Inc Earnings Release

Karuna Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Karuna Therapeutics Inc Earnings Release

Similar to KRTX

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ